Sun Pharmaceutical Industries, soon after agreeing to procure the U. S.-based URL Pharma's generic drugs business, has realized an upsurge in its shares.

The Pharma unit has purchased the business from Japan's Takeda Pharmaceutical Co., raising its own shares by some 2.5%, reaching at $13.72 billion. It has been found that the Sun Pharma has made a second acquisition in the US with this business's possession.

Since, within last two months, the company also purchased Dusa Pharmaceuticals Inc., a skin treatment firm, for $230 million. The latest acquisition value has not been disclosed as yet. However, it has been told that the deal is made on regulatory approvals.

It has been found that URL Pharma was purchased in June last year by Takeda for $800 million. There was also a room for additional payments in case any future performance demanded the same.

Now, the generic assets except Colchicine of URL Pharma would be managed and owned by .S. subsidiary Caraco Pharmaceutical Laboratories of Sun Pharma. Colchicine is used to treat pain and swelling in some conditions.

"The non-Colcrys generic assets of URL Pharma will be owned and managed by Caraco. The deal is subject to satisfaction of customary closing conditions, including applicable regulatory approvals", said Sun Pharma.